tradingkey.logo
tradingkey.logo
Search

Gilead Sciences Inc

GILD
Add to Watchlist
125.160USD
+0.110+0.09%
Close 06/24, 16:00ETQuotes delayed by 15 min
155.39BMarket Cap
16.88P/E TTM

TradingKey Stock Score of Gilead Sciences Inc

Currency: USD Updated: 2026-06-24

Key Insights

Gilead Sciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 16 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 158.05.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Gilead Sciences Inc's Score

Industry at a Glance

Industry Ranking
16 / 157
Overall Ranking
45 / 4571
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Gilead Sciences Inc Highlights

StrengthsRisks
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 29.44B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 814.79%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 814.79%.
Undervalued
The company’s latest PE is 16.88, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.14B shares, decreasing 0.22% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.22.

Analyst Rating

Based on 32 analysts
Buy
Current Rating
158.050
Target Price
+27.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Gilead Sciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of Gilead Sciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Gilead Sciences Inc’s performance and outlook.

How do we generate the financial health score of Gilead Sciences Inc?

To generate the financial health score of Gilead Sciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Gilead Sciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Gilead Sciences Inc.

How do we generate the company valuation score of Gilead Sciences Inc?

To generate the company valuation score of Gilead Sciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Gilead Sciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Gilead Sciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Gilead Sciences Inc.

How do we generate the earnings forecast score of Gilead Sciences Inc?

To calculate the earnings forecast score of Gilead Sciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Gilead Sciences Inc’s future.

How do we generate the price momentum score of Gilead Sciences Inc?

When generating the price momentum score for Gilead Sciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Gilead Sciences Inc’s prices. A higher score indicates a more stable short-term price trend for Gilead Sciences Inc.

How do we generate the institutional confidence score of Gilead Sciences Inc?

To generate the institutional confidence score of Gilead Sciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Gilead Sciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Gilead Sciences Inc.

How do we generate the risk management score of Gilead Sciences Inc?

To assess the risk management score of Gilead Sciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Gilead Sciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Gilead Sciences Inc.
KeyAI